Please add the <u>Abstract</u>, attached hereto on a separate sheet.

## <u>REMARKS</u>

By this Preliminary Amendment, a cross-reference to related applications has been inserted in page 1. The claims have been amended so that the multiple dependency of certain of the dependent claims have been removed to avoid the surcharge associated therewith, and an Abstract is being provided. No new matter has been introduced. Entry of this amendment is respectfully requested.

Respectfully submitted, ELKE POGGE VON STRANDMANN

Rv.

Allison C. Collard, Reg. No.

Edward R. Freedman, Reg. No. 26,048

22.532

Attorneys for Applicant

COLLARD & ROE, P.C. 1077 Northern Boulevard Roslyn, New York 11576 (516) 365-9802

ERF/llv

Enclosure: Exhibit A and an Abstract

EXPRESS MAIL NO. <u>EL 871 451 067 US</u>
Date of Deposit: <u>December 27, 2001</u>

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10, on the date indicated above, and is addressed to BOX PCT, U.S.

Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202.

Lisa L. Vulpis

## EXHIBIT A

## VERSION WITH MARKINGS TO SHOW CHANGES MADE TO CLAIMS 4, 6-8, and 10

- 4. The preparation according to [claims 1, 2 or 3]  $\underline{\text{claim}}$   $\underline{\text{1}}$ , characterized in that the excipient contains a transfer medium transporting the active ingredient.
- 6. The preparation according to [any one of the preceding claims] claim 1, characterized in that it is present in the form of a formula for topical application.
- 7. The preparation according to [any one of claims 1 to 4] <a href="claim 1">claim 1</a>, characterized in that it is present in the form of an injection formula.
- 8. The preparation according to [any one of the preceding claims] claim 1, characterized in that it is intended for the pigmentation or de-pigmentation of skin or hair.
- 10. The use of the protein DCoH, the DNA and/or RNA for the coding of said protein, or DCoH antibodies or DCoH antiserum, as active ingredient for producing a preparation according to [any one of claims 1 to 8] claim 1 for the treatment of pigmentation disorders of the human or animal body.